Trial · NCT00727038
Lucentis for New Onset Neovascular Glaucoma
NCT00727038, Phase 1, Phase 2, Withdrawn, University of Illinois Chicago
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Lucentis for New Onset Neovascular Glaucoma. Trials, record NCT00727038. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00727038
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Lucentis for New Onset Neovascular Glaucoma
- NCT number
- NCT00727038
- Status
- Withdrawn
- Phases
- Phase 1, Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- University of Illinois Chicago
- Conditions
- Glaucoma, New Onset Glaucoma, Neovascular Glaucoma, New Onset Neovascular Glaucoma
- Interventions
- Ranibizumab (Lucentis)
- First posted
- 2008-08-01
- Last updated
- 2020-02-17
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean change in best corrected visual acuity (BCVA) as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters from baseline to Month 6. | Baseline to Month 6. | |
| Secondary | Percent change in angle neovascularization (measured in clock hours by gonioscopy). | Initial visit through Month 6 | |
| Secondary | Percent change in permanent angle closure (clock hours of peripheral anterior synechiae by gonioscopy). | Initial visit through Month 6 | |
| Secondary | Mean change in intraocular pressure measured by applanation tonometry. | Initial visit through Month 6 | |
| Secondary | Percent change in iris neovascularization (measured both in clock hours by slit lamp exam and with iris angiography). | Initial visit through Month 6 | |
| Secondary | Rates of severe vision loss (visual acuity <20/200, loss of 6 lines or more on ETDRS chart). | Initial Visit through Month 6 | |
| Secondary | Number of intraocular pressure lowering medications needed to control intraocular pressure. | Initial Visit through Month 6 | |
| Secondary | Mean change in optic nerve cupping. | Initial Visit through Month 6 | |
| Secondary | Percent of patients requiring surgical glaucoma procedure to control intraocular pressure (trabeculectomy, seton, or ciliary body destruction). | Study duration | |
| Secondary | Percent of patients requiring pars plana vitrectomy with endolaser. | Study duration |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00727038
GET https://conductscience.org/api/trials/v1/NCT00727038/registered